Vir Biotechnology, Inc. (VIR)
NASDAQ • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Vir Biotechnology, Inc. keeps $34 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 4
in 55 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc. develops antibody and infectious-disease medicines and is listed on the NASDAQ Global Select Market under the ticker VIR. The company operates in biotechnology within healthcare, with FY2025 revenue of $68.6 million, and its commercial identity centers on Sotrovimab, marketed as Xevudy for SARS-CoV-2 treatment and prevention.
Today's Snapshot
VIR ended yesterday 3.3% down at 10.81.
Trading Volume
Below 10d avg (2.2M)
1.9M
vs S&P 500 Today
Underperforming Market
-2.83%
Updated: September 10, 2026 at 12:03 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$8.48 - $10.99Buy
- RSI (14)56.83Neutral
- Stochastic %K (14, 3, 3)72.05Neutral
- MACD Level (12, 26)0.53Buy
Peers & Related Assets
Get premium market insights delivered directly to your inbox.